BMO Capital Markets Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)

Equities researchers at BMO Capital Markets began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report issued on Friday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $63.00 price target on the stock. BMO Capital Markets’ price target would suggest a potential upside of 180.25% from the stock’s previous close.

Several other research analysts have also recently weighed in on JSPR. Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Finally, Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $22.48 on Friday. The company’s fifty day simple moving average is $20.54 and its 200-day simple moving average is $20.92. The stock has a market capitalization of $337.20 million, a PE ratio of -4.74 and a beta of 2.18. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its holdings in Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the last quarter. Jane Street Group LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $251,000. Wellington Management Group LLP bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $447,000. State Street Corp increased its holdings in Jasper Therapeutics by 12.3% in the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after acquiring an additional 23,564 shares during the last quarter. Finally, Samsara BioCapital LLC increased its holdings in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.